GSK posted higher profit as sales for its specialty treatments for HIV, cancer and asthma beat expectations, offsetting lower ...

Gilead Sciences agreed to pay $202 million to settle a whistleblower lawsuit accusing the drugmaker of civil fraud for paying ...

A panelist discusses how the HIV patient population has aged significantly, with the average age in their clinic now ...

The Illinois Department of Public Health has issued a standing order that will allow residents to obtain the HIV preventive ...

A Georgia man is facing a felony murder charge after family and prosecutors allege he knowingly did not reveal his ...

Patients in historically redlined neighborhoods experience significantly longer delays in achieving HIV viral suppression ...

The Center in Asbury Park wants people to "Come Early, Stand Proud, and Walk Strong" on May 4 for the New Jersey AIDS Walk ...

Lenacapavir could be a gamechanger in the fight against infection. But US funding cuts have thrown the rollout of the ...

The company paid to settle allegations of paying kickbacks to doctors in exchange for prescribing several of its HIV medicines.

The Federal Ministry of Health and Social Welfare, through the National AIDS, Viral Hepatitis and STIs Control Programme ...

Gilead Sciences on Thursday reported a first-quarter profit, but revenue was flat, as higher sales of drugs for HIV and liver ...

Dolutegravir is recommended by the World Health Organization (WHO) for infants, children and adults and is the preferred HIV ...